RE:Oh my... back to the options story!There he is! Waiting for a moment of "what may appear as a moment of weakness " but then things can change Rather Quickly!....I would Rather be PATIENTLY Waiting then to speak too quick and then disappear in shame:)
My Response Is This:
No "flu season" patient enrolment boom? NOT YET No SP climbing in chunks? NOT YET No early stoppage? NOT YET No acknowledgment by the market of this incredible opportunity? NOT YET Still below 60 cents? FOR NOW (BUY ON ANY WEAKNESS) Then let's talk about options... BUY ON ANY WEAKNESS
The Facts Still Remain The Same:
Enrolment - Initiated 2024 with robust site activity to start the new year:
- Enrolled patient 82 during the first week of January.
- Post-holiday break, strong screening activity resumed with more than 100 patients screened per week.
- Closing in on the interim enrollment target of 90 patients (“Interim Enrollment”); at Interim Enrollment, Baxter International (NYSE.BAX) has the option to make the second non-dilutive milestone payment to Spectral to maintain its PMX exclusive distribution rights.
- Crude mortality results at both 28-day (primary endpoint) and at one year, thus far, continue to exceed efficacy targets. (RIGHT NOW TO DATE)
Trial Sites:
- Near term onboarding of six new, high quality clinical sites.
- Expect significant site onboarding activity during the first quarter of 2024.
YES SLOWER THAN WE WOULD LIKE TO SEE...BUT SLOWLY MOVING IN THE RIGHT DIRECTION PEOPLE!
GLTA True Shareholders!
Rev